Cerevel Therapeutics Holdings, Inc.

NasdaqCM:CERE Rapporto sulle azioni

Cap. di mercato: US$8.2b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Cerevel Therapeutics Holdings Dividendo

Dividendo criteri di controllo 0/6

Cerevel Therapeutics Holdings does not have a record of paying a dividend.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore1.9%
Prossima data di pagamento dei dividendin/a
Data di stacco del dividendon/a
Dividendo per azionen/a
Utile per azione-US$2.53
Previsione del rendimento del dividendo0%

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Apr 30
Cerevel Therapeutics Holdings (NASDAQ:CERE) Has Debt But No Earnings; Should You Worry?

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Jan 02
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Shares Could Be 23% Above Their Intrinsic Value Estimate

Cerevel overweight at Wells Fargo due to candidates with blockbuster potential

Sep 26

Cerevel Therapeutics prices $300M in notes offering, $254M in stock offering

Aug 12

Cerevel Therapeutics GAAP EPS of -$0.61 misses by $0.13

Aug 01

Cerevel: The Next Big Thing In CNS Disease? Maybe If The Market Wasn't So Crowded

Jul 08

Cerevel Therapeutics: Pfizer's Neurology Spin-Off

Jul 14

We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Jun 09
We're Not Very Worried About Cerevel Therapeutics Holdings' (NASDAQ:CERE) Cash Burn Rate

Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Jan 29
Is Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Popular Amongst Institutions?

Cerevel Therapeutics (CERE) Investor Presentation - Slideshow

Nov 18

Cerevel Therapeutics reports Q3 results

Nov 16

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Insufficient data to determine if CERE's dividends per share have been stable in the past.

Dividendo in crescita: Insufficient data to determine if CERE's dividend payments have been increasing.


Rendimento dei dividendi rispetto al mercato

Cerevel Therapeutics Holdings Rendimento dei dividendi rispetto al mercato
Come si colloca il rendimento da dividendo di CERE rispetto al mercato?
SegmentoRendimento dei dividendi
Azienda (CERE)n/a
Fondo del 25% del mercato (US)1.4%
Top 25% del mercato (US)4.3%
Media del settore (Biotechs)1.9%
Analista previsionale (CERE) (fino a 3 anni)0%

Dividendo notevole: Unable to evaluate CERE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Dividendo elevato: Unable to evaluate CERE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Distribuzione degli utili agli azionisti

Copertura degli utili: Insufficient data to calculate CERE's payout ratio to determine if its dividend payments are covered by earnings.


Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Unable to calculate sustainability of dividends as CERE has not reported any payouts.


Scoprire le società che pagano dividendi forti